Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases

PURPOSE: More than 50% of patients with stage IV colorectal cancer (metastatic colorectal cancer [mCRC]) relapse postresection. The efficacy of postoperative systemic treatment is limited in this setting. Thus, these patients would greatly benefit from the use of a reliable prognostic biomarker, suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Loupakis, Fotios, Sharma, Shruti, Derouazi, Madiha, Murgioni, Sabina, Biason, Paola, Rizzato, Mario Domenico, Rasola, Cosimo, Renner, Derrick, Shchegrova, Svetlana, Koyen Malashevich, Allyson, Malhotra, Meenakshi, Sethi, Himanshu, Zimmermann, Bernhard G., Aleshin, Alexey, Moshkevich, Solomon, Billings, Paul R., Sedgwick, Jonathon D., Schirripa, Marta, Munari, Giada, Cillo, Umberto, Pilati, Pierluigi, Dei Tos, Angelo Paolo, Zagonel, Vittorina, Lonardi, Sara, Fassan, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315303/
https://www.ncbi.nlm.nih.gov/pubmed/34327297
http://dx.doi.org/10.1200/PO.21.00101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315303/
https://www.ncbi.nlm.nih.gov/pubmed/34327297
http://dx.doi.org/10.1200/PO.21.00101

Ejemplares similares